Cipla gets CCI nod for investment by FIL Capital
Advertisement
New Delhi: Drug major Cipla said it has received approval from competition watchdog CCI over the proposed investment by Mauritius-based FIL Capital Investments in its consumer healthcare business vertical.
The Competition Commission of India has granted approval to the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the company, Cipla Ltd said in a regulatory filing.
The order of the CCI will be sent to FIL Capital Investments (Mauritius) II Ltd subsequently, it added.
The company however added that "the investment is still subject to, amongst other conditions precedent, approval from the Foreign Investment Promotion Board and the transfer of company's consumer healthcare business to Cipla Health Ltd.
Last year the Mumbai-based drug maker had inked an investment agreement with FIL Capital Investments (Mauritius) II Limited for its consumer healthcare business.
Through the consumer healthcare business, Cipla has entered the over-the-counter (OTC) healthcare market in India.
Earlier, the company's board had approved divestment of its consumer healthcare business to Cipla Health, a wholly- owned subsidiary, by way of a slump sale for a consideration of Rs 10.5 crore
The Competition Commission of India has granted approval to the proposed investment by FIL Capital Investments (Mauritius) II Limited in Cipla Health Limited, subsidiary of the company, Cipla Ltd said in a regulatory filing.
The order of the CCI will be sent to FIL Capital Investments (Mauritius) II Ltd subsequently, it added.
The company however added that "the investment is still subject to, amongst other conditions precedent, approval from the Foreign Investment Promotion Board and the transfer of company's consumer healthcare business to Cipla Health Ltd.
Last year the Mumbai-based drug maker had inked an investment agreement with FIL Capital Investments (Mauritius) II Limited for its consumer healthcare business.
Through the consumer healthcare business, Cipla has entered the over-the-counter (OTC) healthcare market in India.
Earlier, the company's board had approved divestment of its consumer healthcare business to Cipla Health, a wholly- owned subsidiary, by way of a slump sale for a consideration of Rs 10.5 crore
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.